
Palvella Therapeutics Announces Planned Pivotal Phase 3 Study Design of QTORIN 3.9% Rapamycin Anhydrous Gel
WAYNE, PA — Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, recently announced the planned pivotal Phase 3 study design of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), a topical mTOR …
Palvella Therapeutics Announces Planned Pivotal Phase 3 Study Design of QTORIN 3.9% Rapamycin Anhydrous Gel Read More